Formulation Development
Moderna & Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate
Moderna, Inc. and Catalent, Inc. recently announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate…..
Yumanity Therapeutics Announces Strategic Research Collaboration & License Agreement With Merck
Yumanity Therapeutics recently announced it has entered into a strategic research collaboration and license agreement with Merck focused on accelerating….
Mateon & GMP Completed Research & Service Agreement
Mateon Therapeutics, Inc. recently announced that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement entered on….
Esperion & Daiichi Sankyo Europe Announce Amendment to License & Commercial Collaboration Agreement
Esperion recently announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE). ….
AGTC Announces Significant Productivity & Quality Enhancement to Its Proprietary Manufacturing Process
Applied Genetic Technologies Corporation recently provided an update on the continued productivity and quality improvements made in its proprietary manufacturing platform that is….
Provectus Biopharmaceuticals Announces Discovery of Unique PV-10-Induced STING Pathway Mechanism
Provectus recently announce that data from ongoing preclinical study of investigational autolytic cancer immunotherapy PV-10 (rose bengal disodium) was presented at the American Association for…
Catalent Partners With ViralClear Pharmaceuticals on Potential Treatment for COVID-19
Catalent recently announced it has signed an agreement with ViralClear Pharmaceuticals, Inc. to work on the development of a potential treatment for adults with advanced…
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study
Corbus Pharmaceuticals Holdings, Inc. recently announced the last subject completed their final visit in the company’s Phase 2b JBT101-CF-002 trial of lenabasum for the treatment…
uniQure Announces First Two Patients Treated in Phase 1/2 Clinical Trial
uniQure NV recently announced that the first two patients in the Phase 1/2 clinical trial of AMT-130 for the treatment of Huntington’s disease have been…
Onconova Therapeutics Announces Initiation of a Phase 1/2a Study
Onconova Therapeutics, Inc. recently announced an investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) lung adenocarcinoma has begun…
Rubius Therapeutics Highlights Preclinical Data for Oncology Product Candidate
Rubius Therapeutics, Inc. recently announced the presentation of preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of human…
Bionic Sight Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Blindness
Bionic Sight, LLC recently announced it has dosed the first patient in the company’s Phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with….
Nemera & Noble Announce Collaboration to Support Patients Who Self-Administer Medication
Nemera, world leader in design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generic industries, recently announced a collaboration with Noble….
Arch Biopartners Announces FDA Acknowledgement of its IND Application
Arch Biopartners Inc. recently announced the US FDA has received and acknowledged the Investigational New Drug (IND) Application for its lead drug Metablok (LSALT peptide),…
Pfenex Announces US Commercial Launch of Teriparatide Injection
Pfenex Inc. recently announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the US. Teriparatide Injection (also referred to as PF708 and Bonsity)…
Glyscend Therapeutics Completes $20.5-Million Financing Round to Advance Novel Oral Polymer Therapy
Glyscend Therapeutics recently announced the closing of a $20.5-million Series A financing round. Healthcare investors Brandon Capital Partners, through its Medical Research Commercialisation Fund (MRCF),…
Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long-Acting Reversible Contraceptive
Daré Bioscience, Inc. recently announced the receipt by its wholly owned subsidiary of $1.5 million in additional grant funding from the Bill & Melinda Gates…
Phathom Pharmaceuticals Provides Clinical Trial Status Update
Phathom Pharmaceuticals, Inc. recently announced it has randomized the first new patients in each of its two Phase 3 clinical trials since temporarily pausing new…
Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study
Agios Pharmaceuticals, Inc. recently announced that clinical proof-of-concept has been established based on a preliminary analysis in the Phase 1 trial of mitapivat (AG-348) in…
Melinta Therapeutics Enters Agreement to Acquire Tetraphase Pharmaceuticals
Melinta Therapeutics, Inc. recently announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. pursuant to which…
